Hidden Bacteria Supercharges Cancer Growth

Person holding a pink ribbon on a gray shirt
Photo: lovelyday12 / Shutterstock

A common gut bacterium may be helping some breast tumors grow faster and resist chemotherapy, according to new laboratory research.

Story Snapshot

  • Scientists found a toxin-producing strain of Bacteroides fragilis, called ETBF, inside cancerous breast tissue.
  • Lab studies show ETBF speeds up tumor growth and spread in animal models, unlike the harmless version of the same bacteria.
  • A 2024 study linked ETBF to breast tumors that failed to respond to common chemotherapy drugs.
  • Researchers found the bacteria’s toxin latches onto a specific receptor on cancer cells, suggesting a possible new drug target.
  • No human clinical trials have tested whether removing this bacteria helps patients, so the findings remain lab-based for now.

Bacteria Found Inside Breast Tumors

Researchers studying breast cancer found Bacteroides fragilis living inside cancerous breast tissue. A 2021 study published in the journal Cancer Discovery showed that a toxin-making version of the bacteria, known as ETBF, triggered rapid changes in breast tissue cells when it colonized the gut or the mammary glands directly. Those changes included early tissue overgrowth, a known step toward tumor formation.

The same 2021 study tested what happens when ETBF reaches tumors already growing in lab animals. Tumors grew faster and spread more aggressively after exposure to the toxin-producing strain. Importantly, this effect did not happen with the harmless, non-toxic version of the same bacteria species, pointing to the toxin itself as the likely driver.

Link to Chemotherapy Resistance

A 2024 study published in the journal Protein & Cell dug deeper into how this bacteria might affect cancer treatment. Researchers found ETBF was far more common in tumors from patients who did not respond to taxane-based chemotherapy, a standard treatment given before breast cancer surgery. That finding suggests the bacteria may do more than help tumors grow. It may also help them survive treatment.

The same research team identified a specific mechanism. The bacteria’s toxin, called BFT-1, attaches directly to a receptor on cancer cells called NOD1 and makes it more stable. When researchers blocked NOD1 or cleared the bacteria from lab models, cancer cells became more sensitive to chemotherapy and lost some of their stem-cell-like properties that let tumors resist treatment.

Questions Still Need Answers

Scientists have not yet proven that this bacteria causes breast cancer in people. The strongest evidence so far comes from cell cultures, animal experiments, and patient tumor samples examined after diagnosis, not from studies that tracked healthy people over time to see who develops cancer. Researchers acknowledge that detecting bacteria in tumors does not by itself prove the bacteria started the disease.

Breast tissue naturally contains very few bacteria, a problem scientists call low biomass. That makes it harder to rule out contamination during testing and to compare results across different labs. A broader review of cancer-microbiome research found that most studies in this field are snapshots in time rather than long-term tracking studies, which limits how strongly scientists can claim a bacteria causes cancer rather than just appearing alongside it.

What Researchers Want to Study Next

Scientists say the next step is a large study that follows newly diagnosed patients and healthy volunteers over time, tracking tumor tissue, blood, and gut samples to see whether ETBF shows up before cancer develops. They also want independent labs to repeat the chemotherapy-resistance findings in bigger patient groups, broken down by cancer type and stage.

Other researchers hope to test whether clearing the bacteria or blocking its toxin can shrink tumors or restore chemotherapy effectiveness in more realistic models before any human trials begin. For now, the bacteria’s role is a promising lead rather than a confirmed cause, and no treatment based on this research has reached patients.

Johns Hopkins Medicine, which backed some of this research, said the findings add to a growing understanding that microbes living in the body can shape how cancer behaves, not just whether someone gets sick in the first place. That shift in thinking could eventually change how doctors screen for cancer risk or choose treatments, though researchers caution that such applications remain years away from clinical use.

Sources:

wellness.com, academic.oup.com, link.springer.com, pubmed.ncbi.nlm.nih.gov